Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Werewolf Therapeutics, Inc. HOWL
$2.85
+$0.07 (2.52%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
108512989.00000000
-
week52high
7.51
-
week52low
1.39
-
Revenue
16401000
-
P/E TTM
-2
-
Beta
0.21285900
-
EPS
-1.95000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 04:00
Описание компании
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 11 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 19 ноя 2021 г. |
| B of A Securities | Buy | 10 сент 2021 г. | |
| SVB Leerink | Outperform | 25 мая 2021 г. | |
| Jefferies | Buy | 25 мая 2021 г. | |
| EF Hutton | Buy | 05 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | A | 5701056 | 1853000 | 06 янв 2023 г. |
| HICKLIN DANIEL J | A | 295500 | 295500 | 03 янв 2023 г. |
| Lubman Ellen | A | 86200 | 86200 | 03 янв 2023 г. |
| Isaacs Randi | A | 103300 | 103300 | 03 янв 2023 г. |
| Leonard Reid | A | 93600 | 93600 | 03 янв 2023 г. |
| Trost Timothy W. | A | 102800 | 102800 | 03 янв 2023 г. |
| Karunatilake Chulani | A | 103600 | 103600 | 03 янв 2023 г. |
| Seidel-Dugan Cynthia | A | 115900 | 115900 | 03 янв 2023 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 11600 | 11600 | 01 июн 2022 г. |
| Chatterjee Meeta | A | 7733 | 7733 | 01 июн 2022 г. |
Новостная лента
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
GlobeNewsWire
07 февр 2023 г. в 07:00
WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will present virtually at 8:40AM ET on February 16th at the SVB Securities Global Biopharma Conference, taking place February 14th-16th, 2023.
4 Penny Stocks To Buy In January According To Insiders
PennyStocks
20 янв 2023 г. в 14:14
Penny stocks to buy according to these insiders in January. The post 4 Penny Stocks To Buy In January According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
New Strong Buy Stocks for January 20th
Zacks Investment Research
20 янв 2023 г. в 07:32
NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.
New Strong Buy Stocks for January 18th
Zacks Investment Research
18 янв 2023 г. в 09:47
DTEGY, CYN, OKTA, HOWL and ONCY have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.
Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 09:47
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.33% and 18.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?